Hepa Wash reels in €3.8m in series A
This article was originally published in Clinica
Executive Summary
Liver assist device company Hepa Wash (Munich, Germany) plans to initiate clinical studies of its first-generation system after raising €3.8m ($5.6m) in its first venture financing round. The series A financing came from German investment bank KfW Bankengruppe and unnamed private investors. The Hepa Wash procedure uses a proprietary liver dialysis system, comparable to a kidney dialysis machine, which removes protein-bound toxins from the patient's blood in order to stimulate liver function. The procedure has already been evaluated in two preclinical trials. Clinical studies are expected to start in the first half of 2010. According to estimates from the World Health Organization, over 12 million people suffer from liver disease worldwide. The limited number of liver donors means that there is an urgent need for an alternative to liver transplantation to help treat patients with liver failure, according to Hepa Wash.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.